PRTC and SPTX Related Headlines
Go Back- Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug
- PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

